Get the Stockscreener App
918.05
1.32%
-12.30
After Hours:
914.30
-3.75
-0.41%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $918.05, with a volume of 3.44M.
It is down -1.32% in the last 24 hours and down -10.04% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$930.35
Open:
$925
24h Volume:
3.44M
Relative Volume:
1.09
Market Cap:
$819.81B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
40.64
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-8.18%
1M Performance:
-10.04%
6M Performance:
+20.33%
1Y Performance:
+11.62%
1-Day Range:
$905.11
$929.00
1-Week Range:
$905.11
$1,003.22
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
918.05 | 883.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.28 | 586.06B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
208.34 | 391.56B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.42 | 297.77B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
149.81 | 295.52B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly
Eli Lilly (LLY) Reports Positive Phase 3 Pediatric Data for EBGLYSS - Insider Monkey
Eli Lilly (NYSE:LLY) Advances Pediatric Dermatology Growth With Strong S&P 500 - Kalkine Media
Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.4% Following Analyst Downgrade - MarketBeat
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both) (RHHBY) - Seeking Alpha
Eli Lilly Technical Analysis: Is The Selloff Over?Eli Lilly (NYSE:LLY) - Benzinga
High-tech workers, manufacturing legacy helped Lehigh Valley win ‘gauntlet’ for $3.5B Lilly plant - LehighValleyNews.com
Ardsley Dumps 440,000 Hut 8 Shares Worth $19.4 Million - The Motley Fool
Parkland School Board members skeptical of tax break for Eli Lilly - The Morning Call
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? - Yahoo Finance Singapore
Wilmington Savings Fund Society FSB Lowers Stake in Eli Lilly and Company $LLY - MarketBeat
Today's Analyst Rating | HSBC Downgrades Eli Lilly and Co to Sell, J.P. Morgan Cuts Its Price Target Cut on IBM Corp to $283 - 富途牛牛
Portus Wealth Advisors LLC Acquires Shares of 1,675 Eli Lilly and Company $LLY - MarketBeat
Danske Bank A S Buys Shares of 671,064 Eli Lilly and Company $LLY - MarketBeat
Mizuho Markets Cayman LP Acquires 84,404 Shares of Eli Lilly and Company $LLY - MarketBeat
Silvant Capital Management LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Trims Position in Eli Lilly and Company $LLY - MarketBeat
Caitong International Asset Management Buys Eli Lilly Shares - National Today
Pre-market Movement in the U.S. Stock Market: Novo-Nordisk A/S shares fell more than 2% as research results for structure-based obesity drugs approach those of Novo-Nordisk A/S and Eli Lilly and Co. - 富途牛牛
Coldstream Capital Management Inc. Increases Stake in Eli Lilly and Company $LLY - MarketBeat
Cim Investment Management Inc. Cuts Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Lifted by Advisory Services Network LLC - MarketBeat
J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales - BioSpace
Parkland School District considers tax breaks for Eli Lilly’s proposed manufacturing campus - WFMZ.com
How did the Lehigh Valley land the Eli Lilly deal? Company executive offers insight - MSN
'Pennsylvania is winning again': Eli Lilly success story lauded at LVEDC meeting - WFMZ.com
Weight Loss Drug Market Analysis 2026: Leaders, Oral Drugs & Competitive LandscapeNews and Statistics - IndexBox
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
Gov. Josh Shapiro touts Lilly deal as Lehigh Valley celebrates $3.5B investment: "We're competing again" - Lehigh Daily
Eli Lilly’s road to Pennsylvania, details of new $3.5B plant, celebrated in the Lehigh Valley - Lehighvalleylive.com
Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts - Bloomberg.com
Lilly Gets Rare Downgrade as Analysts Question Hype Over GLP-1 Pills and Zepbound's Cash Sales - 富途牛牛
Eli Lilly, Micron among market cap stock movers on Tuesday - Investing.com
Eli Lilly, Micron among market cap stock movers on Tuesday By Investing.com - Investing.com Nigeria
Why Eli Lilly Stock Just Dropped - AOL.com
Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations - Benzinga
Eli Lilly (LLY) Downgraded by HSBC with Lowered Price Target | L - GuruFocus
Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares - AOL.com
Why Eli Lilly’s Hot Streak In Shares Just Broke - TipRanks
Eli Lilly & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why is Eli Lilly stock down today? - Traders Union
Eli Lilly falls after a 6 month rally; is this a buy the dip opportunity? - Invezz
Eli Lilly Stock (LLY) Gets a Rare Downgrade. HSBC Sees This Problem Ahead - TipRanks
Eli Lilly stock drops 3.01% as oversold signals deepen and resistance holds - Traders Union
Eli Lilly, Tencent Music among market cap stock movers on Tuesday - Investing.com
Eli Lilly, Tencent Music among market cap stock movers on Tuesday By Investing.com - Investing.com South Africa
Eli Lilly (LLY) Downgraded by HSBC Amid Concerns Over Market Pot - GuruFocus
Structure Weight-Loss Pill Results Rival Novo, Lilly Treatments - Bloomberg.com
HSBC downgrades Eli Lilly, says shares are ‘priced to perfection’ - Investing.com
HSBC Downgrades Eli Lilly and Company (NYSE:LLY) to Reduce - MarketBeat
Eli Lilly and Company $LLY Position Reduced by Mairs & Power Inc. - MarketBeat
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):